The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Lung cancer treatment: where are we now?
New lung cancer therapies are constantly being developed and approved. Indeed, the new treatments on the market have rendered chemotherapy increasingly redundant. Matti Aapro, MD, of the Clinique de Genolier, Genolier, Switzerland, spoke to us about this exciting new treatment landscape at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. He discusses TKIs, immunotherapy, and the importance of continued adherence to guidelines and good scientific practice in the face of so many potential treatments.
